Nothing Special   »   [go: up one dir, main page]

CL2020001146A1 - Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb). - Google Patents

Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).

Info

Publication number
CL2020001146A1
CL2020001146A1 CL2020001146A CL2020001146A CL2020001146A1 CL 2020001146 A1 CL2020001146 A1 CL 2020001146A1 CL 2020001146 A CL2020001146 A CL 2020001146A CL 2020001146 A CL2020001146 A CL 2020001146A CL 2020001146 A1 CL2020001146 A1 CL 2020001146A1
Authority
CL
Chile
Prior art keywords
hbv
virus
hepatitis
pyrazolopiperidine
high activity
Prior art date
Application number
CL2020001146A
Other languages
English (en)
Inventor
Alastair Donald
Andreas Urban
Susanne Bonsmann
Anita Wegert
Jasper Springer
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of CL2020001146A1 publication Critical patent/CL2020001146A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE, EN GENERAL, A NUEVOS AGENTES ANTIVIRALES. ESPECÍFICAMENTE, LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS QUE PUEDEN INHIBIR LA PROTEÍNA O PROTEÍNAS CODIFICADA(S) POR EL VIRUS DE LA HEPATITIS B (VHB) O INTERFERIR CON LA FUNCIÓN DEL CICLO DE REPLICACIÓN DEL VHB, A COMPOSICIONES QUE COMPRENDEN ESTOS COMPUESTOS, A MÉTODOS PARA INHIBIR LA REPLICACIÓN DEL VIRUS VHB, A MÉTODOS PARA TRATAR O PREVENIR LA INFECCIÓN POR VHB Y A PROCESOS O INTERMEDIOS PARA FABRICAR LOS COMPUESTOS.
CL2020001146A 2017-11-02 2020-04-30 Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb). CL2020001146A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17199676 2017-11-02

Publications (1)

Publication Number Publication Date
CL2020001146A1 true CL2020001146A1 (es) 2020-10-09

Family

ID=60201937

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001146A CL2020001146A1 (es) 2017-11-02 2020-04-30 Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).

Country Status (22)

Country Link
US (1) US11236087B2 (es)
EP (1) EP3704119A1 (es)
JP (1) JP2021501768A (es)
KR (1) KR20200083552A (es)
CN (1) CN111527087A (es)
AR (1) AR115131A1 (es)
AU (1) AU2018361365C1 (es)
BR (1) BR112020008765A2 (es)
CA (1) CA3081399A1 (es)
CL (1) CL2020001146A1 (es)
CU (1) CU20200045A7 (es)
EA (1) EA202091114A1 (es)
EC (1) ECSP20029569A (es)
GE (1) GEP20227374B (es)
IL (1) IL274297A (es)
MA (1) MA50520A (es)
MX (1) MX2020004838A (es)
PH (1) PH12020550531A1 (es)
SG (1) SG11202003746UA (es)
TW (1) TW201925199A (es)
UY (1) UY37961A (es)
WO (1) WO2019086142A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202003700TA (en) * 2017-11-02 2020-05-28 Aicuris Gmbh & Co Kg Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
AR117188A1 (es) * 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb)
UY38436A (es) * 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
UY38434A (es) * 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
US20220218661A1 (en) * 2018-11-29 2022-07-14 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation
SG11202111198QA (en) * 2019-04-30 2021-11-29 Aicuris Gmbh & Co Kg Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
US20220306647A1 (en) * 2019-04-30 2022-09-29 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitus b virus (hbv)
WO2020247504A1 (en) 2019-06-06 2020-12-10 Aligos Therapeutics, Inc. Heterocyclic compounds
PE20221327A1 (es) 2019-12-20 2022-09-09 Bayer Ag Carboxamidas de tiofeno, acidos carboxilicos de tiofeno sustituidos y derivados de estos
CN116829571A (zh) 2020-11-23 2023-09-29 英安塔制药有限公司 新型螺旋吡咯烷衍生的抗病毒药物
WO2022235605A1 (en) 2021-05-04 2022-11-10 Enanta Pharmaceuticals, Inc. Novel macrocyclic antiviral agents
US11919910B2 (en) 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
WO2023086352A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
WO2023137007A1 (en) 2022-01-11 2023-07-20 Enanta Pharmaceuticals, Inc. Processes for the preparation of 4,6,7-trifluoro-1h-indole-2-carboxylic acid
CN116396204B (zh) * 2023-03-29 2024-09-24 无锡科华生物科技有限公司 一种4,6,7-三氟-1h-吲哚-2-羧酸的制备方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19817264A1 (de) 1998-04-18 1999-10-21 Bayer Ag Neue Dihydropyrimidine
AU4289100A (en) 1999-03-25 2000-10-16 Bayer Aktiengesellschaft Dihydropyrimidines and their use in the treatment of hepatitis
AU3009801A (en) 1999-12-22 2001-07-03 Bayer Aktiengesellschaft Combinations of medicaments for treating viral diseases
DE10012823A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
CN102060857A (zh) * 2000-08-10 2011-05-18 辉瑞意大利有限公司 具有激酶抑制剂活性的二环吡唑类、其制备方法和包含它们的药物组合物
EP1608364A1 (en) 2003-03-11 2005-12-28 Pharmacia Italia S.p.A. Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2006033995A2 (en) 2004-09-16 2006-03-30 Valeant Research And Development Thiazolidin-4-ones having anti-hepatitis b activity
US7842810B2 (en) 2005-03-31 2010-11-30 Janssen Pharmaceutica, Nv Bicyclic pyrazole compounds as antibacterial agents
WO2007022280A1 (en) 2005-08-16 2007-02-22 Memory Pharmaceuticals Corporation Phosphodiesterase 10 inhibitors
US8309578B2 (en) 2008-11-25 2012-11-13 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
WO2011067145A1 (en) 2009-12-04 2011-06-09 Nerviano Medical Sciences S.R.L. Tricyclopyrazole derivatives
WO2012114252A1 (en) * 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
JP5977347B2 (ja) 2011-07-01 2016-08-24 バルーク エス．ブルームバーグ インスティテュート Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体
KR101939710B1 (ko) 2011-12-21 2019-01-17 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
EP2800742B1 (en) 2012-01-06 2016-04-06 Janssen Sciences Ireland UC 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b
AR092269A1 (es) 2012-08-28 2015-04-08 Janssen R&D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
MY174042A (en) 2012-08-28 2020-03-05 Janssen Sciences Ireland Uc Fused bicyclic sulfamoyl derivative and the use thereof as medicaments for the treatment of hepatitis b.
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
AU2014267235B2 (en) 2013-05-17 2017-10-05 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP2997032B1 (en) 2013-05-17 2018-07-25 F.Hoffmann-La Roche Ag 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN108047115B (zh) 2013-07-25 2021-06-29 爱尔兰詹森科学公司 经乙醛酰胺取代的吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
WO2015057945A1 (en) 2013-10-18 2015-04-23 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
CA2928003A1 (en) 2013-11-14 2015-05-21 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis b infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
ES2714110T3 (es) 2014-03-07 2019-05-27 Hoffmann La Roche Heteroarildihidropirimidinas 6-fusionadas novedosas para el tratamiento y profilaxis de la infección por el virus de la hepatitis B
PT3116316T (pt) 2014-03-13 2019-09-30 Assembly Biosciences Inc Moduladores alostéricos da proteína do núcleo da hepatite b
US9771358B2 (en) 2014-03-28 2017-09-26 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
US9695166B2 (en) 2014-05-05 2017-07-04 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
CA2948580A1 (en) 2014-05-09 2015-11-12 Adam Zlotnick Methods and compositions for treating hepatitis b virus infections
US20150375115A1 (en) 2014-06-30 2015-12-31 Microsoft Corporation Interacting with a story through physical pieces
EP3180319B1 (en) 2014-08-14 2018-10-03 F.Hoffmann-La Roche Ag Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection
WO2016086200A1 (en) 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
DK3227262T3 (da) 2014-12-02 2020-08-10 Novira Therapeutics Inc Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling
EP3240787A4 (en) 2014-12-30 2018-06-20 Novira Therapeutics Inc. Derivatives and methods of treating hepatitis b infections
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
EP3270915B1 (en) 2015-03-16 2020-04-15 H. Hoffnabb-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
CN107624113B (zh) 2015-05-04 2020-10-23 豪夫迈·罗氏有限公司 作为HBsAg (HBV 表面抗原)和HBV DNA 生成的抑制剂用于治疗乙型肝炎病毒感染的四氢吡啶并嘧啶和四氢吡啶并吡啶类化合物
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017011552A1 (en) 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2017013046A1 (en) 2015-07-21 2017-01-26 F. Hoffmann-La Roche Ag Novel tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
WO2017015451A1 (en) 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
TWI730985B (zh) 2015-09-15 2021-06-21 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
JP6845231B2 (ja) 2015-09-29 2021-03-17 ノヴィラ・セラピューティクス・インコーポレイテッド Ｂ型肝炎抗ウイルス薬の結晶形態
WO2017076286A1 (zh) 2015-11-04 2017-05-11 南京明德新药研发股份有限公司 二氢吡啶并环化合物的晶型、制备方法和中间体
WO2017136403A1 (en) 2016-02-02 2017-08-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2017155844A1 (en) 2016-03-07 2017-09-14 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
CN109153682B (zh) 2016-05-20 2021-05-25 豪夫迈·罗氏有限公司 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物
EP3484886B1 (en) 2016-07-14 2020-03-04 Hoffmann-La Roche AG 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
WO2018011160A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
JP7034133B2 (ja) 2016-07-14 2022-03-11 エフ．ホフマン－ラ ロシュ アーゲー 感染性疾患の処置のためのカルボキシ ６，７－ジヒドロ－４Ｈ－ピラゾロ［１，５－ａ］ピラジン化合物
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CA3036245C (en) 2016-09-13 2021-07-20 Arbutus Biopharma Corporation Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
CN110621672A (zh) 2017-03-02 2019-12-27 组装生物科学股份有限公司 环状磺酰胺化合物及其使用方法
EP3601216B1 (en) 2017-03-21 2023-10-25 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection

Also Published As

Publication number Publication date
AU2018361365B2 (en) 2021-04-01
WO2019086142A1 (en) 2019-05-09
PH12020550531A1 (en) 2021-03-22
BR112020008765A2 (pt) 2020-10-20
TW201925199A (zh) 2019-07-01
EA202091114A1 (ru) 2020-07-24
CN111527087A (zh) 2020-08-11
SG11202003746UA (en) 2020-05-28
MX2020004838A (es) 2020-10-16
CA3081399A1 (en) 2019-05-09
AU2018361365C1 (en) 2021-08-05
AR115131A1 (es) 2020-12-02
JP2021501768A (ja) 2021-01-21
GEP20227374B (en) 2022-04-25
CU20200045A7 (es) 2021-03-11
MA50520A (fr) 2020-09-09
AU2018361365A1 (en) 2020-05-21
IL274297A (en) 2020-06-30
US11236087B2 (en) 2022-02-01
US20210179608A1 (en) 2021-06-17
EP3704119A1 (en) 2020-09-09
KR20200083552A (ko) 2020-07-08
ECSP20029569A (es) 2020-07-31
UY37961A (es) 2019-05-31

Similar Documents

Publication Publication Date Title
CL2020001146A1 (es) Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
CL2020001145A1 (es) Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb).
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
UY38434A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
UY37997A (es) Agentes antivirales contra la hepatitis b
CL2018002528A1 (es) Agentes anti virales de la hepatitis b.
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
UY38436A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
ECSP21031082A (es) Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
UY37998A (es) Agentes antivirales contra la hepatitis b
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
CO2019009215A2 (es) Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c
ECSP21079317A (es) Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
ECSP21078893A (es) Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb)
UY38435A (es) Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
ECSP21080338A (es) Nuevas oxalil piperazinas activas contra el virus de la hepatitis b (vhb)
UY38439A (es) Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
UY38681A (es) Nuevas indolizina-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
AR111017A1 (es) Sal hemisulfato de un compuesto nucleotídico para el tratamiento del virus de la hepatitis c
EA202092602A2 (ru) -d-2'-дезокси-2'--фтор-2'--c-замещенные-2-модифицированные-n6-замещенные пуриновые нуклеотиды для лечения вызванных hcv заболеваний